Debut Plus

211.43

+2.13 +1.02%

As of 10 Sept 2026 · delayed

NSE Listed

LT-ASM · ASM 1
What does LT-ASM · ASM 1 mean?
BSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-07-09
NSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-07-14

IOL Chemicals & Pharmaceuticals Ltd. (IOLCP)

Volume: 32,34,389Avg Vol 1W: 54,38,667.4Avg Vol 1M: 49,31,165.352W Range:67.19219.04
Key Ratios
Checked 8h ago
Market Cap₹5,869 Cr
Current Price₹211.43
Previous Close₹209.3
High / Low (52w)₹219.04 / ₹67.19
Volume32,34,389
Avg Vol (1W)54,38,667.4
Avg Vol (1M)49,31,165.3
Stock P/E17.79
Book Value₹57.49
Dividend Yield
ROE6.1%
ROA
Revenue (TTM)₹2,102 Cr
Revenue Growth
Profit Margin
Total Debt₹0 Cr
Shares Outstanding
Face Value₹2
EPS (TTM)₹3.44
P/B1.06
Debt / Equity0.05
50 DMA₹169.08
200 DMA₹112.64
Day change+1.02%
SurveillanceLT-ASM · ASM 1
Price Chart
211.43 86.18% · 1Y
213684.1Cr
2025-09-10
2026-09-10

20-day avg volume: 49.3L shares

Pros
  • Company is almost debt-free.
Quarterly Results
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹526 Cr₹523 Cr₹528 Cr₹552 Cr₹568 Cr₹580 Cr₹619 Cr₹756 Cr
EBITDA₹30 Cr₹32 Cr₹49 Cr₹50 Cr₹44 Cr₹42 Cr₹74 Cr₹90 Cr
Net Profit₹19 Cr₹21 Cr₹31 Cr₹34 Cr₹30 Cr₹21 Cr₹53 Cr₹64 Cr
EPS
Profit & Loss (Annual)
MetricMar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Mar 2026Jun 2026
Revenue₹528 Cr₹2,102 Cr₹552 Cr₹568 Cr₹580 Cr₹619 Cr₹2,340 Cr₹756 Cr
EBITDA₹49 Cr₹153 Cr₹50 Cr₹44 Cr₹42 Cr₹74 Cr₹210 Cr₹90 Cr
Net Profit₹32 Cr₹101 Cr₹34 Cr₹30 Cr₹21 Cr₹53 Cr₹138 Cr₹64 Cr
EPS3.444.69
Balance Sheet
MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹1,170 Cr₹1,610 Cr₹1,962 Cr₹2,022 Cr₹2,244 Cr₹2,382 Cr₹2,587 Cr
Total Liabilities₹356 Cr₹350 Cr₹570 Cr₹514 Cr₹633 Cr₹694 Cr₹788 Cr
Equity₹814 Cr₹1,260 Cr₹1,392 Cr₹1,508 Cr₹1,612 Cr₹1,688 Cr₹1,799 Cr
Total Debt₹0 Cr₹0 Cr
Cash Flow
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹522 Cr₹156 Cr₹169 Cr₹332 Cr₹197 Cr₹252 Cr
Investing₹-317 Cr₹-121 Cr₹-120 Cr₹-191 Cr₹-154 Cr₹-198 Cr
Financing₹-58 Cr₹-2 Cr₹-4 Cr₹-92 Cr₹46 Cr₹-29 Cr
Free Cash Flow₹522 Cr₹156 Cr₹169 Cr₹332 Cr₹197 Cr₹252 Cr
Shareholding
Promoter 62.28% Institutions 5.31% Public 32.42%
Efficiency & Working Capital
ROCE10.3%
Interest Coverage13.7
Dividend Payout
Debtor Days95 d
Inventory Days58 d
Payable Days76 d
Cash Conversion Cycle77 d
Working Capital Days153 d
Shareholding Details

As of 2026-06-30

Promoter62.3%
FII4.9%
DII0.4%
Institutions5.3%
Public32.4%
Promoter Pledge0%
No. of Shareholders1,19,311
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters48.2%48.2%48.2%48.2%48.2%52.6%52.6%52.6%52.6%52.6%57.5%62.3%
FIIs2.3%2.2%1.4%1.4%1.6%1.5%1.5%2.6%2.2%2.1%1.7%4.9%
DIIs0.4%0.4%0.3%0.1%0.1%0.1%0.1%0%0%0%0%0.4%
Public49.1%49.3%50.1%50.3%50.1%45.8%45.8%44.8%45.1%45.3%40.8%32.4%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders1,35,3971,34,2351,30,0031,28,6891,25,9791,26,7011,30,0021,25,0401,36,1291,33,5311,31,5501,19,311
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603
Major Shareholders (>1%)
NameCategoryStakeShares
Nm Merchantiles LimitedShareholding of Promoter and Promoter Group21.9%6.42 Cr
Maya Devi Polycot LimitedShareholding of Promoter and Promoter Group21.8%6.39 Cr
Ncvi Enterprises LimitedShareholding of Promoter and Promoter Group16.6%4.87 Cr
Varender GuptaShareholding of Promoter and Promoter Group2%59,79,325
Dimple GuptaShareholding of Promoter and Promoter Group0%0
Vikas GuptaShareholding of Promoter and Promoter Group0%0
Abhiraj GuptaShareholding of Promoter and Promoter Group0%0
Varinder Gupta (huf)Shareholding of Promoter and Promoter Group0%5,500
Vikas Gupta (huf)Shareholding of Promoter and Promoter Group0%0
Board of Directors
NameDesignationYear
R M MallaChairman & Independent Directo2026
Varinder GuptaExecutive Director & MD2026
Vikas GuptaExecutive Director / JMD / WTD2026
Abhiraj GuptaE D & Wholetime Director2026
Kushal Kumar RanaExecutive Director (Works)2026
Harpal SinghIndependent Non Exe. Director2026
SHARAD TYAGIIndependent Non Exe. Director2026
Rajni JhaIndependent Non Exe. Director2026
Abhay Raj SinghSVP / Company Secretary / Compliance Officer2026
Segments — Product
SegmentRevenueShare
Chemicals₹923 Cr39.8%
Drugs₹1,396 Cr60.2%
Segments — Geography
RegionRevenueShare
India₹1,755 Cr75.7%
Switzerland₹53 Cr2.3%
Indonesia₹47 Cr2%
Rest of the world₹465 Cr20%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹2805959
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-10Board Meetings
dividend2026-02-17₹1 (50%)Interim
forthcomingBook ClosureAGM
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
202610023155179
202600002223
202610023132156
Insider / Designated-Person Trades

5 recent disclosure(s)

NCVI Enterprises LimitedAcquisition · 4,04,305
Mayadevi Polycot LimitedAcquisition · 54,197
NCVI Enterprises LimitedAcquisition · 7,00,000
NCVI Enterprises LimitedAcquisition · 7,00,000
Mayadevi Polycot LimitedAcquisition · 6,54,123
Substantial Acquisitions (SAST)

2 disclosure(s)

Off Market25/06/2026 · 1,40,83,195
Off Market17/10/2025 · 1,15,78,195
Company Information
Incorporated1986
ChairmanR M Malla
AuditorAshwani & Associates
🌐 www.iolcp.com

📍 Trident Complex, Raikot Road Barnala, Sangrur, Punjab, 148101

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search